Protagenic Therapeutics IncFRA Protagenic Stock Report

Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York. The firm specializes in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-residue peptide synthetic TCAP-1. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. PT00114 has also demonstrated pre-clinical efficacy in a murine model of opioid withdrawal called the Saleens test. The company is building a TCAP platform to address various neuropsychiatric disorders and other neurodegenerative diseases that are impacted by the stress response system of the brain.